SCHEMBL206975

SCHEMBL206975

CCOC(=O)Cc1csc(Nc2nc(-c3ccc(Cl)cc3)cs2)n1

nearest known ligand 0.76

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.76
SMN1; SMN2 Q16637 5/20 0.76
KMT2A Q03164 4/20 0.64
GAA P10253 3/20 0.62
KDM4E B2RXH2 1/20 0.62
ALDH1A1 P00352 1/20 0.60
MEN1 O00255 3/20 0.59
LMNA P02545 3/20 0.59
CYP1A2 P05177 2/20 0.59
CYP3A4 P08684 2/20 0.59
CYP2C9 P11712 2/20 0.59
CYP2C19 P33261 2/20 0.59
KCNH2 Q12809 1/20 0.59
POLB P06746 2/20 0.57
HPGD P15428 1/20 0.53
ABL1 P00519 1/20 0.53
TP53 P04637 1/20 0.53
CFTR P13569 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL208387 0.83 RAB9A (0.58) MAPTSMN1; SMN2KMT2AGAAALDH1A1
SCHEMBL2073208 0.80 MAPT (0.65) MAPTSMN1; SMN2KMT2AGAAKDM4E
SCHEMBL13731275 0.80 L3MBTL1 (0.60) MAPTSMN1; SMN2KMT2AGAAALDH1A1
SCHEMBL3547359 0.80 MAPT (0.80) MAPTSMN1; SMN2KMT2AKDM4EALDH1A1
SCHEMBL3620152 0.78 KMT2A (1.00) MAPTSMN1; SMN2KMT2AGAAKDM4E
SCHEMBL11009364 0.75 SMN1; SMN2 (0.69) MAPTSMN1; SMN2KMT2AGAAALDH1A1
SCHEMBL11376337 0.74 SMN1; SMN2 (0.67) MAPTSMN1; SMN2KMT2AGAAALDH1A1
SCHEMBL6220893 0.73 MAPT (0.74) MAPTSMN1; SMN2KMT2AGAAALDH1A1
SCHEMBL24101421 0.73 MAPT (0.77) MAPTSMN1; SMN2KMT2AGAAKDM4E
SCHEMBL6520420 0.72 GAA (0.77) MAPTSMN1; SMN2KMT2AGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 MAPT 2207/4885SMN1; SMN2 3252/4885KMT2A 3476/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 MAPT 2207/4885SMN1; SMN2 3252/4885KMT2A 3476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.